CHEMMEDCHEM 润色咨询

ChemMedChem

出版年份：2006 年文章数：2794 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：4.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2017-05-21 Ryan-CLF

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2018-06-06 ms5054295132918558

    jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2017-01-31 ms8843322981934364

    审稿速度:1.0
    经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2016-12-21 ms4829174089086404

    审稿速度:3.0
    经验分享：与药无关的文章可以刊登吗？谢谢！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2016-12-21 ms313574960747337

    投稿命中率:75.0
    经验分享：与药无关的文章可以刊登吗？谢谢！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2015-07-05 jianchibux2015

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2012-11-02 ms1549354653385798

    sci也收录了
    例：
    abstracting and indexing information：
    medline (nlm)
    ?mosby yearbooks (elsevier)
    ?science citation index (thomson reuters)
    ?science citation index expanded (thomson reuters)
    ?scopus

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2012-06-12 sangfeng

    审稿速度:2.0 | 投稿命中率:75.0
    经验分享：还不错，只是为人知之甚少

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2012-03-06 ms9430612511402566

    if=3.306（2010年）

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=536947, encodeId=589853694e91, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：审稿速度其实很快，一个月一审，修回后两天后接收，正式版本上传后第二天网页上就可以查到未排版文件。 EJMC后比较好的投稿选择。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ab31678956, createdName=Ryan-CLF, createdTime=Sun May 21 10:21:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=843784, encodeId=b5e7843e84d5, content=jmc，ejmc之后非常值得推荐的药物化学期刊，编辑超级认真！！！！！！！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62635414138, createdName=ms5054295132918558, createdTime=Wed Jun 06 17:33:39 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835395, encodeId=c99a83539556, content=审稿速度:1.0<br>经验分享：审稿真快，2017_01_10投出，回家过年，2017_01_31正月初四收到直接accept，太幸运了。这篇文章有点意外，12月26号投medchemcomm12月30号拒稿。之后1月6号改投bmc隔夜被拒。最后10号改投chemmedchem。确实没想到if反而越投越高。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60585414036, createdName=ms8843322981934364, createdTime=Tue Jan 31 15:32:06 CST 2017, time=2017-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835024, encodeId=3f7183502412, content=审稿速度:3.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54f75414053, createdName=ms4829174089086404, createdTime=Wed Dec 21 10:59:59 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=835023, encodeId=ef0e8350237a, content=投稿命中率:75.0<br>经验分享：与药无关的文章可以刊登吗？谢谢！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3de05414115, createdName=ms313574960747337, createdTime=Wed Dec 21 10:59:52 CST 2016, time=2016-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=513238, encodeId=1d9351323891, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：博士期间中了一篇，费了好长时间。主要是审稿人给了大修，补充数据，返修后还是大修。结果推迟了大半年才接受。毕业的同学就不要投稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=390, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ab1621492, createdName=jianchibux2015, createdTime=Sun Jul 05 16:13:00 CST 2015, time=2015-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=822313, encodeId=43a48223138d, content=sci也收录了<br> 例：<br> abstracting and indexing information：<br> medline (nlm) <br> ?mosby yearbooks (elsevier) <br> ?science citation index (thomson reuters) <br> ?science citation index expanded (thomson reuters) <br> ?scopus , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78fc5414021, createdName=ms1549354653385798, createdTime=Fri Nov 02 12:03:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=488895, encodeId=8e604888953d, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：还不错，只是为人知之甚少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=533, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b5462721, createdName=sangfeng, createdTime=Tue Jun 12 22:11:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=818397, encodeId=f87c81839e48, content=if=3.306（2010年） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a95414072, createdName=ms9430612511402566, createdTime=Tue Mar 06 11:39:00 CST 2012, time=2012-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=815364, encodeId=509b8153646f, content=比biomc难一点，但是质量应该好一点 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17a5413995, createdName=ms4097232105300978, createdTime=Mon Jul 18 19:36:00 CST 2011, time=2011-07-18, status=1, ipAttribution=)]
    2011-07-18 ms4097232105300978

    比biomc难一点，但是质量应该好一点

    0

共12条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分